Pulse Biosciences (NASDAQ:PLSE) Trading 7.6% Higher – Here’s Why

Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) shot up 7.6% during mid-day trading on Tuesday . The stock traded as high as $16.34 and last traded at $16.34. 33,479 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 200,741 shares. The stock had previously closed at $15.19.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research note on Friday, September 20th.

Pulse Biosciences Stock Performance

The company’s 50-day moving average is $17.38 and its two-hundred day moving average is $14.44.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period last year, the company posted ($0.19) earnings per share.

Institutional Trading of Pulse Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its stake in shares of Pulse Biosciences by 63.6% in the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock valued at $66,000 after acquiring an additional 2,952 shares during the last quarter. Inspire Investing LLC raised its position in Pulse Biosciences by 32.1% in the first quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock valued at $360,000 after purchasing an additional 10,039 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Pulse Biosciences by 28.8% during the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after purchasing an additional 189,227 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Pulse Biosciences during the first quarter worth about $88,000. Finally, Cetera Advisors LLC acquired a new position in shares of Pulse Biosciences in the first quarter valued at approximately $109,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.